When does Invokana’s exclusivity end in Canada?
Invokana (canagliflozin) is expected to lose market exclusivity in Canada based on the timeline tied to its key Canadian patent(s) and related exclusivity protections. However, the exact “loss of exclusivity” date depends on which specific protection is being considered (e.g., the last patent protecting marketing, not regulatory timelines alone).
For a current, patent-by-patent view of when Invokana’s exclusivity is expected to end in Canada, see DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “Invokana” or “canagliflozin”). [1]
What “lose exclusivity” usually means for patients and generic makers
In Canadian drug markets, the date people refer to as “loss of exclusivity” generally lines up with when generic manufacturers can seek to launch without being blocked by the remaining qualifying patent rights listed by the brand company under Canada’s drug patent linkage process. The precise launch readiness date can differ from the last patent expiry depending on litigation and whether any subsequent patents are listed or enforced.
Because of that, looking at the specific last-protecting patent(s) and their expiry dates is the most reliable way to estimate exclusivity loss. [1]
Can Invokana generics launch immediately after the exclusivity date?
Not always. Even after the latest patent expiry shown in public sources, brand and generic companies may have ongoing patent disputes or other regulatory steps that affect actual launch timing. That’s another reason patent-expiry timelines should be checked directly in a database that tracks Canadian listings and related events. [1]
Where to verify the exact date
The most practical way to get the exact Canada exclusivity/expiry date for Invokana is to verify the “last expiry” (and any relevant extensions) for canagliflozin on DrugPatentWatch.com, where the entries are updated as patent information changes. [1]
Sources:
[1] https://www.drugpatentwatch.com/